In MS and T2DM, the level of GLP-1, its secretion in response to food intake and the activity of GLP-1 signaling system are reduced, leading to the disturbances of insulin sensitivity, energy metabolism and neurogenesis [324,330,331]. Here, INS is linked to myeloid sarcoma.